Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026

뉴스 본문을 불러오고 있어요.

Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026 | 웨이프 WAPE

Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026

기사 요약

관련 종목

댓글 —